Why the study?
While dobutamine is commonly used for inotropic support in ADHF with reduced ejection fraction, its safety and efficacy remain debated, and levosimendan has emerged as a potential alternative.
Does levosimendan reduce 30-day all-cause mortality compared to dobutamine in adults with acute decompensated heart failure?
Does levosimendan reduce 30-day all-cause mortality compared to dobutamine in adults with acute decompensated heart failure?
In a meta-analysis of 8 RCTs, levosimendan significantly reduced 30-day all-cause mortality and shortened hospital stay compared to dobutamine in patients with acute decompensated heart failure.
No takes yet. Share an insight, caveat, or question.
Supports levosimendan over dobutamine in acute decompensated heart failure; confirms mortality benefit across 8 RCTs.
Parente et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: